Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16021159 | 0.86 | MCL1 (0.47) | L3MBTL1MCL1ALDH1A1ADRA1AALOX5AP | |
| SCHEMBL28230701 | 0.86 | ALOX5AP (0.46) | L3MBTL1MCL1ALDH1A1ADRA1AALOX5AP | |
| SCHEMBL3941612 | 0.86 | MCL1 (0.50) | L3MBTL1MCL1ALDH1A1PDE2ATHRB | |
| SCHEMBL14299188 | 0.83 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL25362679 | 0.82 | MCL1 (0.51) | L3MBTL1MCL1ALDH1A1PDE2ATHRB | |
| SCHEMBL14684308 | 0.82 | ADRA1A (0.43) | L3MBTL1MCL1ALDH1A1ADRA1AALOX5AP | |
| SCHEMBL9303098 | 0.82 | ABCB11 (0.52) | MCL1ADRA1AALOX5APFEN1ABCB11 | |
| SCHEMBL6191403 | 0.82 | PDIA6 (0.49) | L3MBTL1MCL1ALOX5APFEN1KIF11 | |
| SCHEMBL29458370 | 0.82 | PDIA6 (0.49) | L3MBTL1MCL1ALOX5APFEN1KIF11 | |
| SCHEMBL19019674 | 0.81 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1ADRA1AALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MERCK PATENT GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-7589112-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2009-09-15 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191423-A1 | Isoquinoline derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | L3MBTL1 3477/4885MCL1 881/4885ALDH1A1 1382/4885 |
| US-20090298885-A1 | METHYLENE UREA DERIVATIVES | BRAF, RAF1, CMPK1 | L3MBTL1 3485/4885MCL1 394/4885ALDH1A1 748/4885 |
| US-20070191423-A1 | Isoquinoline derivatives | ABL1, MAP3K1, MAP3K2 | L3MBTL1 4784/4885MCL1 357/4885ALDH1A1 2329/4885 |
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | L3MBTL1 3485/4885MCL1 394/4885ALDH1A1 748/4885 |
| US-20090253688-A1 | Semicarbazide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP3K2 | L3MBTL1 4810/4885MCL1 851/4885ALDH1A1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.